![Michael Goller](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Goller
Directeur/Membre du Conseil chez
DBV TECHNOLOGIES
Fortune : - $ au 31/05/2026
Profil
Michael J.
Goller is currently a Director at DBV Technologies SA since 2015, a Director at Terremoto Biosciences, Inc., an Independent Director at Replimune Group, Inc. starting in 2025, and a Partner at Baker Bros.
Advisors LP since 2005.
Former roles include Director at diaDexus, Inc. from 2005 to 2010, Director at Levo Therapeutics, Inc. from 2017 to 2019, Independent Non-Executive Director at BeOne Medicines Ltd. from 2015 to 2026, Associate at J.P.
Morgan Partners LLC from 1993 to 2003, and Investment Banker at Merrill Lynch & Co., Inc. from 1997 to 1999.
Education includes graduate and Masters of Business Administration degrees from The Wharton School of the University of Pennsylvania and an undergraduate degree from The Pennsylvania State University conferred in 1997.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
BEONE MEDICINES LTD. -.--% | 22/05/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
DBV TECHNOLOGIES SA -.--% | 15/04/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Michael Goller
| Sociétés | Poste | Début |
|---|---|---|
| DBV TECHNOLOGIES | Directeur/Membre du Conseil | 21/10/2015 |
| REPLIMUNE GROUP, INC. | Directeur/Membre du Conseil | 05/03/2025 |
Baker Bros. Advisors LP
 Baker Bros. Advisors LP Investment ManagersFinance BBA pursues a fundamentally driven approach to life sciences investing. The firm typically takes large, concentrated positions in the securities of life sciences companies with the potential for significant value creation over the long-term. They focus on public securities, but may, from time to time, recommend investments in private companies, life sciences and related healthcare intellectual property, royalty streams or other non-public investment opportunities. | Analyst-Equity | 01/01/2005 |
Terremoto Biosciences, Inc.
 Terremoto Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage company which develops drugs for oncology and genetic diseases | Directeur/Membre du Conseil | - |
Anciens postes connus de Michael Goller
| Sociétés | Poste | Fin |
|---|---|---|
| BEIGENE LTD | Directeur/Membre du Conseil | 11/06/2026 |
Levo Therapeutics, Inc.
 Levo Therapeutics, Inc. BiotechnologyHealth Technology Engages in research into therapeutics | Directeur/Membre du Conseil | 01/02/2019 |
diaDexus, Inc. /Old/
 diaDexus, Inc. /Old/ Medical SpecialtiesHealth Technology Develops and markets diagnostic products | Directeur/Membre du Conseil | 01/11/2010 |
J.P. Morgan Partners LLC
 J.P. Morgan Partners LLC Investment ManagersFinance J.P. Morgan Partners provides financing for growth capital, corporate acquisitions, LBOs, special situations and recapitalizations. The firm invests globally across a variety of sectors including consumer, media, energy, industrial, financial services, healthcare and technology | Corporate Officer/Principal | 01/01/2003 |
Merrill Lynch & Co., Inc.
 Merrill Lynch & Co., Inc. Investment ManagersFinance Provides wealth management, securities trading and sales, corporate finance and investment banking services | Corporate Officer/Principal | 01/01/1999 |
Formation de Michael Goller
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
78
Relations au 1er degré
11
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
diaDexus, Inc. /Old/
diaDexus, Inc. /Old/ Medical SpecialtiesHealth Technology Develops and markets diagnostic products | Health Technology |
Baker Bros. Advisors LP
Baker Bros. Advisors LP Investment ManagersFinance BBA pursues a fundamentally driven approach to life sciences investing. The firm typically takes large, concentrated positions in the securities of life sciences companies with the potential for significant value creation over the long-term. They focus on public securities, but may, from time to time, recommend investments in private companies, life sciences and related healthcare intellectual property, royalty streams or other non-public investment opportunities. | Finance |
J.P. Morgan Partners LLC
J.P. Morgan Partners LLC Investment ManagersFinance J.P. Morgan Partners provides financing for growth capital, corporate acquisitions, LBOs, special situations and recapitalizations. The firm invests globally across a variety of sectors including consumer, media, energy, industrial, financial services, healthcare and technology | Finance |
The Pennsylvania State University
 The Pennsylvania State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
DBV Technologies SA
 DBV Technologies SA Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that focuses on changing the field of immunotherapy | Health Technology |
Merrill Lynch & Co., Inc.
Merrill Lynch & Co., Inc. Investment ManagersFinance Provides wealth management, securities trading and sales, corporate finance and investment banking services | Finance |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Replimune Group, Inc.
 Replimune Group, Inc. BiotechnologyHealth Technology Develops oncolytic immunotherapies | Health Technology |
BeiGene Ltd.
 BeiGene Ltd. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Health Technology |
Levo Therapeutics, Inc.
Levo Therapeutics, Inc. BiotechnologyHealth Technology Engages in research into therapeutics | Health Technology |
Terremoto Biosciences, Inc.
Terremoto Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage company which develops drugs for oncology and genetic diseases | Health Technology |
